

10/575348

Express Mail mailing label number ED 756213836 US
Date of Express Mail deposit: April 7, 2006

Attorney Docket No. AC-02-US

JAP15 Rec'd PCT/PTO 07 APR 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bezencon, et al.)	Examiner: TBD
)	
Serial No.: TBD)	Group Art Unit: TBD
)	
(National Stage of PCT/EP2004/011088))	
)	
Filed: October 5, 2004)	Attorney Docket: AC-02-US
)	
Title: Novel Tetrahydropyridine Derivatives)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 C.F.R. §1.97 *et. seq.*, Applicant provides the enclosed materials for the Examiner's consideration in connection with the above-identified patent application.

Applicant respectfully requests that this Information Disclosure Statement and the documents listed on the attached Form 1449 and enclosed herewith be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Copies of foreign documents and communication from a foreign patent office are enclosed herein.

The information contained in this Information Disclosure Statement is not to be construed as 1) a representation that a search has been conducted; 2) additional information


IAP15 Rec'd PCT/PTO 07 APR 2006

material to the examination of this application does not exist; 3) the information, protocol, results and the like reported by third parties are accurate or enabling; the information is considered to be material to patentability; or 4) that the information constitutes prior art to the current application.

It is believed that no fee is required. If a fee is required, please charge the same to Deposit Account No. 50-3464. The Examiner is invited to contact the Applicant's representative at the telephone number listed below if there are any questions.

Respectfully submitted,

Date: April 7, 2006



Thomas Hoxie
Reg. No. 32,993

HOXIE & TSO LLP
374 Millburn Avenue
Suite 300E
Millburn, New Jersey 07041
973-467-2126

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	TBD
Filing Date	April 7, 2006
First Named Inventor	BEZENCON, et al.
Group Art Unit	TBD
Examiner Name	TBD

10/575348

Sheet 1 of 1

Attorney Docket No: AC-02-US

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2003/0013883 A1	01/16/2003	Tamagnan et al.	
	2002/0004513 A1	01/10/2002	Andersson et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	WO 04/002957 A1	01/08/2004	Bezencon et al.		
	WO 04/096803 A1	11/11/2004	Bezencon et al.		
	WO 04/096804 A1	11/11/2004	Bezencon et al.		
	WO 04/096799 A1	11/11/2004	Bezencon et al.		
	WO 04/096366 A1	11/11/2004	Bezencon et al.		
	WO 04/096116 A2	11/11/2004	Bezencon et al.		
	WO 04/096116 A3	11/11/2004	Bezencon et al.		
	WO 04/105762 A1	12/09/2004	Bur et al.		
	WO 03/093267 A1	11/13/2003	Bezencon et al.		
	WO 01/60823 A1	08/23/2001	Cignarella et al.		
	WO 97/09311	03/13/1997	Binggeli et al.		
	WO 92/05174	04/02/1992	King et al.		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARKI, H.P. et al. <i>Piperidine renin inhibitors: from leads to drug candidates</i> , IL Farmaco, 2001, pages 21-27, Vol. 56.	
		CHEN, Z. et al. <i>Synthesis and Dopamine Transporter Affinity of 2-(Methoxycarbonyl)-9-methyl-3-phenyl-9-azabicyclo[3.3.1]nonane Derivatives</i> , J. Med. Chem., 1996, pages 4744-4749, Vol. 39, No. 24.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached